National Institute of Allergy and Infectious Diseases; Opportunity for a Cooperative Research and Development Agreement (CRADA) for the Clinical Development of a Live, Attenuated Cold-Adapted Influenza Virus Vaccine(s)

Riepilogo

The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health announces its intention to make available, to all interested and capable parties, information related to the clinical development of a live, attenuated cold-adapted influenza virus vaccine(s). Briefly, under IND 601 (Investigational New Drug #), the NIAID has supported the clinical research development of this experimental vaccine(s). The NIAID is interested in having these efforts utilized for the public good by transferring this information to a company with an interest in the development and licensure of the cold-adapted vaccine. The information in the IND 601 will be available for confidential evaluation to interested and capable parties for a period of 45 days. This information will be made available to representatives of companies at a site in Bethesda, Maryland, following the execution of a Confidentiality Agreement. Copies of the material may be made at this site, by company representatives, at a nominal fee to cover copying cost. Following this 45 day evaluation period, the NIAID will entertain proposals from any companies interested in pursuing the development of this pr